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Abstract
Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency disorder 
associated with microthrombocytopenia, eczema, autoimmunity and predisposition to 
malignant lymphoma. Although rare, few cases of somatic mosaicism have been published in 
WAS patients to date. We here report on two Ukrainian siblings who were referred to us at 
the age of 3 and 4 years, respectively. Both patients suffered from severe WAS caused by a 
nonsense mutation in exon 1 of the WAS gene. In both siblings, flow cytometric analysis 
revealed the presence of WASp-positive and WASp-negative cell populations amongst T and 
B lymphocytes as well as NK cells. In contrast to previously described cases of revertant 
mosaisicm in WAS, molecular analyses in both children showed that the WASp-positive T 
cells, B cells, and NK cells carried multiple different second-site mutations, resulting in 
different missense mutations. To our knowledge, this is the first report describing somatic 
mosaicism in WAS patients caused by several independent second-site mutations in the WAS
gene. 
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Introduction
Wiskott-Aldrich syndrome (WAS) is a complex primary immunodeficiency disorder 
characterized by microthrombocytopenia, eczema, autoimmune phenomena, and 
susceptibility to malignant lymphoma. WAS, the defective gene in this disorder, encodes for 
Wiskott-Aldrich syndrome protein (WASp), a key regulator of actin polymerization (1). 
WASp deficiency causes multiple cellular defects, including defective leukocyte migration, 
defective T cell proliferation and disturbed formation of the immunological synapse (2, 3). 
Several cases of revertant mosaicism have been described for WAS (4-9). The observation 
that the genetic reversion in a single or few cells can give rise to somatic mosaicism supports 
the concept that WASp expression confers a selective advantage at least for T lymphocytes 
and NK cells, which has important implications for the prospect of gene therapy  approaches 
for this disorder (10).
We here report on two 3- and 4-year old siblings suffering from WAS with a novel nonsense 
mutation in exon 1 of the WAS gene, in both of whom somatic mosaicism for WASp was 
observed. Molecular investigations provided evidence for several independent second-site 
mutations in both patients. This observation adds to the growing understanding of somatic 
mosaicism in WAS.
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Materials and Methods
Patients and controls
All material from patients and healthy donors was obtained with informed assent/consent in 
accordance with the Declaration of Helsinki. 
Flow cytometry
Immunophenotyping and flow cytometric analysis of WASp expression in peripheral blood 
mononuclear cells (PBMCs) were performed as described previously (9, 11). 
T cell proliferation assays
T cell proliferation assays were performed as described previously with minor modifications 
(12). In brief, T cell stimulation was performed using anti-CD3 coated 96 well plates with or 
without additional human IL-2 at a final concentration of 10 IU/ml. Cells were stimulated for 
48 hours before pulsing with 1µCi (0.037 MBq) of 3H-Thymidine (Perkin Elmer, Jügesheim, 
Germany) for 24 hours and subsequent analysis of thymidine incorporation.
Podosome staining
CD14+ cells were labelled with anti-CD14 magnetic beads (Milteny Biotech, Bergisch 
Gladbach, Germany) and isolated using an AutoMACS device (Milteny Biotech). Podosome 
analysis was performed as described previously (13).
Molecular analysis
CD3-positive lymphocytes from both patients were sorted into fractions of WASp-positive 
and WASp-negative cells. Genomic DNA was extracted from both fractions, followed by 
PCR amplification of all 12 exons of the WAS gene including intron-exon boundaries. For 
exons 1-11, PCR amplification was performed at an annealing temperature of 60°C using the 
following primer pairs: exon 1 fw: gctcagcctaacgaggagg, exon 1 rev: cgggaaattctaggagaggag, 
exon 2 fw: ctgcagctcttcctttggg, exon 2 rev: ctgatcaggtctgaggtcttg, exons 3-5 fw: 
ctcccaaatccagacaccc, exons 3-5 rev: ccctcctcttctctctggg, exon 6 fw: ccagccaatgaaggtgagtc, 
exon 6 rev: tcaatctacctatccattcaccc, exon 7 fw: tccatgaccatccaacacac, exon 7 rev: 
cagccatctgcccatctg, exons 8-9 fw: cattcattaattctggcccc, exons 8-9 rev: tgaccaactcctgactgaagc, 
exon 10 fw: gtcaggagttggtcagtggg, exon 10 rev: ctaaggcctggcactctcc, exon 11 fw: 
gaaggggactggagtgtgtg, exon 11 rev: acagatggggctgatgtcac. Primers and PCR conditions for 
amplification of exon 12 have been published previously (14). DNA sequences were analyzed 
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by using an ABI Prism 3130 DNA Sequencer and the DNA Sequencing Analysis software 
version 3.4 (Applied Biosystems, Foster City, CA, USA) and Sequencer version 3.4.1 (Gene 
Codes Corporation, Ann Arbor, USA).
To demonstrate the presence of several independent second-site mutations, exon 1 of the WAS
gene in the WASp-positive and WASp-negative CD3+ lymphocyte, the WASP-positive CD3-
CD56+ NK cell fraction and B cell population (sorted as CD3-CD56-CD19+CD20+ cells) 
was amplified using the primer pair described above. The product was gel extracted and 
subcloned into PCR Script cloning vector (Stratagene, Amsterdam, Netherlands). Sequencing 
of clones was performed using M13 universal primers. 
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Results
In August 2006, two brothers suffering from Wiskott-Aldrich syndrome were referred to us as 
potential candidates for a clinical gene therapy study. At this point, the brothers were 4 
(patient 1) and 3 years (patient 2) of age, respectively. Patient 1 had eczema from birth and 
suffered from bloody diarrhea since infancy. At the age of 3 years, the patient had a systemic 
CMV infection. Patient 2 also suffered from eczema since birth. Due to a marked bleeding 
diathesis, he had  frequent severe epistaxis. Both patients suffered from recurrent upper 
respiratory tract infections. 
We performed T cell proliferation assays in both patients and found decreased proliferative 
responses upon CD3 stimulation, which could be partially rescued by additional stimulation 
with hIL-2 (Fig. 1a). Furthermore, we performed podosome analysis in peripheral blood 
CD14+ monocytes and found complete absence of podosomes in both patients, while a 
healthy control displayed 65% podosome-positive monocytes (Fig. 1b). Both patients had less 
than 50,000 platelets/microliter (Table 1). Immunophenotyping revealed decreased numbers 
of B lymphocytes in both patients as well as inverted CD4-CD8 ratios (Table 1). IgG levels in 
both patients were within the normal range. Specific antibodies to vaccines were dissociated. 
Patient 1 mounted a protective response to tetanus (0.11 IU/ml) but not to diptheria (0.08 
IU/ml). Patient 2 had 0.15 IU/ml anti-tetanus-IgG and 0.18 IU/ml anti-diptheria IgG. 
Flow cytometric analysis of WASp expression in peripheral blood mononuclear cells was 
performed and revealed the presence of fractions of WASp-positive and WASp-negative cells 
amongst CD3+ lymphocytes and NK cells in both patients (Fig. 2). In both patients, the 
majority of CD8+ lymphocytes and NK cells were WASP-positive. A fraction of 31% of 
CD4+ lymphocytes were positive in the elder brother (patient 1), whereas only a minor 
fraction of 4% of CD4+ cells were positive in the younger brother (patient 2). A small 
fraction of B lymphocytes from both patients were also WASp-positive, whereas no WASP-
positive cells were identified in monocytes (Fig. 2). 
We next performed flow cytometric sorting of WASp-positive and WASp-negative CD3+ 
lymphocytes from both patients, extracted DNA and sequenced all 12 exons of the WAS 
gene. The WASp-negative cell fraction harboured a novel mutation in exon 1, leading to a 
premature stop codon (c.C58T; p.Q20X). In contrast, analysis of the WASp-positive cell 
fraction showed an ambiguous signal for nucleotides 2 and 3 of the triplet of interest (Fig. 3). 
Thus, our findings suggested that the WASp+ CD3+ lymphocytes contained cells with 
different second-site mutations within the same triplet. The chromatograms showed that, for 
the WASp+ cell fraction, the „dominant” triplet was TAT in patient 1 and TGG in patient 2 
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while different peaks representing other nucleotides at triplet position 2 and 3 were also 
apparent. 
To confirm the suspected molecular heterogeneity of WASp+ CD3+ cells, we sorted 
peripheral T cells into WASP-positive and WASP-negative fractions. Exon 1 of the WAS gene 
was PCR amplified and subcloned into a cloning vector prior to sequence analysis. 48 
individual clones from patient 1 and 52 clones from patient 2 were analyzed by sequence 
analysis. In patient 1, we found that 23 out of 48 clones carried the triplet TAT, while 16 
clones carried the triplet TGG and 9 clones carried the triplet TAC. For patient 2, 36 out of 52 
clones carried the triplet TGG, whereas other clones carried the triplet TAC (13/52), TTG 
(1/52) or the wildtype sequence CAG (1/52) (Fig. 3). 1 out of 52 clones contained the original 
mutation TAG, thus representing missorted cells. 
In contrast to WASp+ CD3+ cells, the chromatograms for WASp+ NK cells suggested the 
presence of a predominant TGG triplet for both patients. We found that 19 out of 20 clones 
from patient 1 contained the TGG sequence, while one clone contained the triplet TAC. For 
patient 2, 10 clones were analyzed, all of which contained the triplet TGG.  Since also a minor 
B cell population appeared to be reverted in both patients (Fig. 2), we also sorted CD3-CD56-
CD19+CD20+ B lymphocytes, subcloned the amplified exon 1 and subjected 123 clones from 
patient 1 and 114 clones from patient 2 to sequence analysis. 115 out of 123 sequences 
(93.5%) for patient 1 and 110 out of 114 sequences (96.5%) for patient 2 carried the original 
mutation, respectively. The second-site mutations in B lymphocytes from patient 1 were 
identified as CAG (4 out of 123), TGG (3) and TAC (1). For patient 2, 3 clones carried the 
triplet TAT and 1 clone the triplet TAC, respectively.
At a clinical follow up of the two patients 18 months later, both patients had decreased 
bleeding and eczema. Interestingly, their thrombocyte counts had risen to normal values. 
However, immunophenotypic analysis showed that both patients had persistent B cell 
lymphopenia. The CD4-CD8 ratio remained inverted (Table 1). 
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Discussion
Wiskott-Aldrich syndrome is a complex, X-linked primary immunodeficiency disorder caused 
by mutations in the WAS gene (2). More recently, a series of cases  of somatic mosaicism 
have been reported for WAS (4-9). Spontaneous in vivo reversion events have also been 
reported for other primary immunodeficiency disorders such as ADA-SCID (15), X-linked 
SCID (16), Leukocyte Adhesion Deficiency (LAD) (17) or X-linked immunodeficiency with 
ectodermal dysplasia due to mutations in NEMO (18). While the majority of cases of somatic 
mosaicism in WAS is caused by true back reversions,  more rare scenarios of a second-site 
mutations leading to altered but functional gene products has also been observed (5, 6). The 
study of somatic mosaicsim due to secondary somatic mutations is of considerable interest for 
the prospect of gene therapy for WAS, as it supports the concept of a potential proliferative 
advantage of gene-corrected cells at least for T lymphocytes and NK cells (10).
The cases presented here are remarkable in several aspects. Our analyses show that both 
affected siblings have somatic mosaicism for WAS with the large majority of CD8+ 
lymphocytes and NK cells expressing WAS protein. Indeed, observations by Wada et al. have 
demonstrated increasing expansion of WASp-positive lymphocytes over time in a WAS 
patient with revertant mosaicism (6), in agreement with the proliferative advantage of gene-
corrected lymphocytes evident in the Was knockout mouse model (12). Given the high 
proportion of WASp+ cells in both patients, one may hypothesize that the second-site 
mutations may have occurred early in life. An alternative explanation may be that the 
proliferative advantage for WASp-positive lymphoid cells is particularly strong in these 
patients due to the severity of the null mutation in exon 1. 
Sequencing results for the WASp-positive cell fractions suggested the parallel presence of 
different sequences within the same triplet in which the original mutation occurred, thus 
representing different second-site mutations. Indeed, we were able to confirm at a molecular 
level that both siblings carry at least 3 different second-site mutations within their WASp-
positive CD3+ lymphocytes. Interestingly, the distribution of the detected second-site 
mutations is not equal in both siblings. First, the predominant sequence is different for the two 
patients, with the majority of cells carrying the triplet TAT for patient 1 and the triplet TGG 
for patient 2. Secondly, some of the observed triplets are either unique to one of the siblings 
or extremely rarely found in the other sibling, i.e., the triplet TAT was found exclusively in 
patient 1 and the triplets TTG and the wildtype triplet CAG were found exclusively in patient 
2. Nonetheless, in contrast to the variety of second-site mutations found in WASp+ CD3+ 
cells, almost the entire set of WASp+ NK cells from both patients contained the triplet TGG. 
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We also found second-site mutations in B cells, consistent with our FACS data which showed 
that a minor population of B lymphocytes were WASp-positive in both patients. 
An open question is whether the altered WAS protein is indeed functional. We have attempted 
to express the altered WAS protein in a retroviral vector system but could not achieve 
sufficient protein expression levels. Longitudinal observation of these patients suggests that 
they may have a clinical benefit from the second-site mutations, with an overall decreased 
bleeding diathesis and eczema in both patients. Of note, their platelet counts normalized. 
However, these observations remain anecdotal. In a clinical perspective, it remains difficult to 
define parameters guiding rational therapeutic decisions in WAS patients showing 
spontaneous somatic chimerism. Should allogeneic bone marrow transplantation or 
experimental gene therapy be performed in these patients? In view of the inherent difficulty in 
judging the consequences of retrovirus-mediated WASp expression, we decided not to offer 
experimental gene therapy at the present time.  
Although there is increasing evidence that the prevalence of spontaneous somatic mosaicism 
in WAS patients may be higher than previously recognized, we here present, to the best of our 
knowledge, the first cases of somatic mosaicism caused by multiple second-site mutations in 
the same patients. The precise mechanism underlying these findings is unclear at present, but 
it is an intriguing observation that all second-site mutations have occurred within the same 
triplet. This would suggest that this triplet may be a hotspot for mutational events, a concept 
which is also supported by the finding that both siblings carry second-site mutations in this 
triplet. On the other hand, no other mutations within this triplet have been described in WAS 
patients to date (19) (http://homepage.mac.com/kohsukeimai/wasp/WASPbase.html.). An 
alternative hypothesis could be environmental influences which the patients may have 
experienced, such as exposure to increased amounts of radioactivity in many areas in Ukraine 
following the incident in Chernobyl in 1986. It is tempting to speculate if only such 
mutational events which confer a proliferative advantage to cells such as true back mutations 
or second-site mutations leading to an altered but functional protein, may eventually be 
observed in the patients, whereas many other mutations may remain undetected.
Prospective multicenter longitudinal studies would greatly help to define the clinical spectrum 
of reversions and their functional and molecular implications – these data are urgently needed 
to define a practical approach to the clinical management of WAS patients with somatic 
mosaicism.
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Figure legends
Figure 1.
T cell proliferation assay and podosome analysis in CD14+ cells. (a) T cell proliferation upon 
stimulation with CD3 was decreased in both patients as compared to a healthy donor.  This 
was partially rescued upon co-stimuation with human IL-2. (b) Podosomes were absent in 
CD14+ cells from both patients, whereas 65% of healthy donor CD14+ cells were podosome-
positive.
Figure 2.
Intracytoplasmic WASp expression analysis by FACS. Histograms represent staining anti-
WASp staining (filled lines) as compared to isotype control (open lines) in different leukocyte 
subsets as indicated. 
Figure 3.
Molecular analysis of second-site mutations in both patients. CD3+ WASp+ cells were 
FACSsorted and exon 1 of the WASp gene was sequenced, with the chromatogram showing 
ambiguous signals for nucleotide positions 2 and 3 in the triplet of interest. Subcloning of the 
DNA and subsequent sequence analysis demonstrated the presence of multiple second-site 
mutations in both patients.  
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Table 1. Blood counts and immunophenotyping in patients 1 and 2.
Patient 1
Aug 2006
Patient 1
Feb 2008
Patient 2
Aug 2006
Patient 2
Feb 2008
Reference 
values 
Leukocytes [/µl] 5200 10625 7900 7125 4,000-10,000
Thrombocytes [/µl] 45000 260000 20000 280000 150,000-300,000
Lymphocytes [/µl] 3822 3835 1358 3129 1,000-5,300
CD3+ cells [/µl] 2320 1981 727 3835 800-3,500
CD3+CD4+ cells [/µl] 791 677 308 1228 400-2,100
CD3+CD8+ cells [/µl] 1333 1348 392 2818 200-1,200
CD19+ cells [/µl] 144 187 91 84 200-600
CD3-CD56+ cells [/µl] 226 961 456 2141 70-1,200
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